3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Breast Neoplasms
24
Colorectal Neoplasms
19
Stomach Neoplasms
15
Rectal Neoplasms
13
Triple Negative Breast Neoplasms
10
Pancreatic Neoplasms
7
Neoplasm Metastasis
7
Nasopharyngeal Carcinoma
6
Colonic Neoplasms
6
Neoplasms
4
Gallbladder Neoplasms
4
Cholangiocarcinoma
4
Anus Neoplasms
4
Adenocarcinoma Of Esophagus
4
Esophageal Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Somatostatinoma
2
Recurrence
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Klatskin Tumor
2
Esophageal Squamous Cell Carcinoma
2
Colorectal Cancer Metastatic
2
Clinical Stage I Gastric Cancer AJCC v8
2
Biliary Tract Neoplasms
2
Adenoma, Islet Cell
2
Squamous Cell Carcinoma of Head and Neck
1
Spinocerebellar Degenerations
1
Solid Cancer
1
Skin Neoplasms
1
Rectal Diseases
1
Interventions
lutetium Lu 177 dotatate
2
pasireotide
1
copper dotatate CU-64
1
amino-acid, glucose, and electrolyte solution
1
abemaciclib
1
Temozolomide
1
Receptor-Like Protein Tyrosine Phosphatases, Class 2
1
Oxaliplatin
1
Octreotide
1
Nivolumab
1
Lutetium-177
1
Lutetium
1
Leucovorin
1
Ipilimumab
1
Folfox protocol
1
Fluorouracil
1
Everolimus
1
E-7386
1
Capecitabine
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
11-(2-methylpropyl)-12,13-dihydro-2-methyl-8-(pyrimidin-2-ylamino)-4H-indazolo(5,4-a)pyrrolo(3,4-c)carbazol-4-one
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Gastro-enteropancreatic neuroendocrine tumor
×
Capecitabine
×
Clear all
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled